• DNase I (GMP-grade): Documented Scope

  2026-10-15

  The available APExBIO product information identifies DNase I (GMP-grade), SKU K1088R, but does not provide a product description, activity specification, formulation, quality documentation, or identity-matched research study. A cautious interpretation is therefore limited to the enzyme class named by the product and to the distinction between DNA degradation as an upstream mechanism and any downstream nucleic-acid measurement.

• Cy3 Maleimide: Mechanism and Evidence Limits

  2026-10-15

  APExBIO describes Cy3 maleimide (non-sulfonated), SKU A8138, as a thiol-reactive Cy3 fluorophore for covalent labeling of cysteine-containing biomolecules and thiol-modified oligonucleotides. The documented chemistry and optical specifications support a product-level interpretation, but no identity-matched research paper is available to establish labeling efficiency, selectivity in complex samples, imaging performance, or biological compatibility.

• ECL Western Blotting Substrate: Evidence and Scope

  2026-10-14

  APExBIO’s K2187 is documented as a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent immunoblots. The available evidence establishes its intended measurement role and broad product claims, but provides no matched peer-reviewed study, quantitative performance data, or independent comparison with other substrates.

• NF 449: Evidence for Selective P2X1 Blockade

  2026-10-14

  NF 449 is supported by recombinant-receptor evidence as a highly potent antagonist of P2X1-containing channels, but its selectivity and platelet relevance depend on biological context. The key study does not by itself establish efficacy in native platelets, animal thrombosis, or clinical antithrombotic use.

• Sequential Mitochondrial Transplantation in IRI

  2026-10-13

  This ACS Nano study presents a preclinical strategy for myocardial ischemia-reperfusion injury that combines early local mitochondrial support with later systemic supplementation. Its findings are promising but remain limited by the condensed evidence available, absent quantitative outcomes, and uncertain translation to human care.

• Netrin-1 and Adipose Remodeling in Obesity

  2026-10-12

  A mouse study reports that adipose-derived Netrin-1 may hinder compensatory adipose remodeling during excess-calorie exposure by suppressing adipogenic differentiation through PPARγ and Wnt/β-catenin signaling. The findings are mechanistically suggestive but remain preclinical and do not establish a human treatment strategy.

• What the IEM-1925 Soman Study Shows

  2026-10-12

  A 2026 rat study evaluated IEM-1925 as a dual AMPA/NMDA glutamate-receptor antagonist after soman-induced status epilepticus. It reported improved survival, seizure control, hippocampal preservation and behavioral outcomes, but the findings are preclinical and should not be generalized to IEM 1460, human treatment or nerve-agent exposure outside the study context.

• Smurf1 and Cisplatin Sensitivity in Colorectal Cancer

  2026-10-11

  Guo and colleagues investigated whether Smurf1 expression influences colorectal cancer response to gemcitabine and Cisplatin (CDDP). Across HCT116 cell, cell-derived xenograft, and patient-derived xenograft models, reduced Smurf1 was associated with greater drug-related apoptosis and antitumor effects. The findings support Smurf1 as a preclinical chemosensitivity marker, but they do not establish clinical efficacy, patient selection criteria, or a treatment strategy.

• Annexin V-HF647/PI Kit for ESCC Apoptosis

  2026-10-10

  Explore how the Annexin V-HF647/PI Apoptosis Kit can support careful interpretation of apoptosis phenotypes in esophageal squamous cell carcinoma research, using the HOXC9–AKT/mTOR study as a framework for separating observed cell death from mechanistic inference.

• Deracoxib: Evidence in Canine Osteosarcoma

  2026-10-09

  Deracoxib is a selective COX-2 inhibitor with established relevance to veterinary pain and inflammation research, while its anticancer evidence remains primarily cell-based. This overview examines the strongest supplied study, compares its findings with catalog-level claims, and defines the limits of translating in-vitro cytotoxicity into clinical oncology conclusions.

• Gamma-Linolenic Acid: Evidence in Context

  2026-10-09

  A source-grounded overview of Gamma-linolenic acid (GLA), covering its proposed inflammatory mechanisms, evidence quality, interpretation of laboratory findings, clinical scope and key limitations. The supplied vaccine study concerns arachidonic acid rather than GLA, so it cannot establish a GLA benefit.

• Biomimetic Nanotherapy for Metastatic TNBC

  2026-10-08

  Cheng and colleagues developed a biomimetic nanoplatform that combines photothermal tumor ablation with immune remodeling for metastatic triple-negative breast cancer. The study is notable for integrating tumor-cell-membrane targeting, stimulus-responsive release, an immune adjuvant, and checkpoint-related peptide activity, while remaining preclinical and model-dependent.

• Methotrexate Beyond Mechanism: Translational Strategy

  2026-10-08

  Methotrexate is more than a DHFR inhibitor: its polyglutamate persistence, phase-dependent effects, and adenosine-linked immunomodulation create a translational opportunity—and a measurement challenge. This thought-leadership article connects mechanistic biology with biomimetic membrane models while defining the evidence boundaries researchers should respect.

• FGF10 and the Next Strategic Layer of CAR-M

  2026-10-07

  CAR-M therapy is moving from a cell-engineering question toward a systems-biology challenge: how can engineered macrophages remain active, selective, and compatible with tissue context? This analysis examines the 2026 in situ CAR-M study in hepatocellular carcinoma and positions Recombinant Human FGF10 as a hypothesis-generating tool for studying that broader translational landscape.

• Drosophila Keap1, Lamin, and Nuclear Architecture

  2026-10-07

  Carlson and colleagues identify a functional connection between Drosophila Keap1 and the B-type lamin lamin Dm0, linking xenobiotic-response signaling with nuclear lamina organization and heterochromatin distribution. The findings broaden the biological scope of Keap1 beyond transcriptional control of detoxification genes, while remaining dependent on evidence from a Drosophila developmental model.

8631 records 1/576 page Next 12345 下5页 Last page